TP53INP2 and acute myeloid leukemia: Notably, we observed that OCI-AML3 cells that naturally carried NPM1-mA exhibited greater TP53INP2 levels and greater sensitivity to TRAIL treatment than did other AML cells, prompting us to speculate whether NPM1-mA is involved in regulating the effect of TP53INP2 on TRAIL activity.